Related by context. All words. (Click for frequent words.) 72 relapsers 68 virologic failure 68 chlorambucil 67 CR nPR 67 splenectomized patients 66 definite stent thrombosis 66 TEAEs 65 virologic response 65 tirofiban 65 Doxil ® 65 virological response 65 virological failure 65 Timed Walk 65 null responders 64 mg kg dose 64 metastatic RCC 64 methotrexate monotherapy 64 eplerenone 64 infliximab 64 achieve sustained virologic 64 colorectal liver metastases 64 Kaplan Meier analysis 64 CCyR 64 CsA 64 peginterferon 63 morphometric vertebral fractures 63 biochemical relapse 63 HBeAg negative patients 63 paricalcitol 63 TNF inhibitor 63 HBeAg positive patients 63 FOLFIRI 63 evaluable 63 placebo p = 63 beta blocker therapy 63 β blockers 63 noninferiority 63 binary restenosis 63 DMARD 63 plus ribavirin 63 PSADT 62 p = .# [002] 62 achieved sustained virological 62 prior relapsers 62 dasatinib 62 nondiabetic patients 62 metastatic renal cell carcinoma 62 severe exacerbations 62 ribavirin therapy 62 periprocedural MI 62 FOLPI 62 sirolimus eluting stent 62 mRCC 62 serum HCV RNA 62 infliximab therapy 62 progression TTP 62 periprocedural 62 liver metastases 62 rFVIIa 62 complete cytogenetic 62 μmol L 62 FOLFOX4 62 bosentan 62 abciximab 62 curative resection 61 preoperative chemotherapy 61 cytogenetic response 61 5-FU/LV 61 plus dexamethasone 61 achieved statistical significance 61 receiving VICTRELIS 61 ribavirin RBV 61 detectable HCV RNA 61 univariate 61 viral kinetics 61 evaluable patients 61 gefitinib 61 coronary stenosis 61 mycophenolate mofetil 61 glycoprotein IIb IIIa inhibitors 61 XIENCE V PROMUS Stent 61 secondary efficacy endpoints 61 Flu Cy 61 heavily pretreated 61 biochemical recurrence 61 stage IIIB 61 intravesical therapy 61 CR CRu 61 prior chemotherapy regimens 61 neoadjuvant chemotherapy 61 prospectively defined 61 LVEF 61 anthracycline containing 61 contrast induced nephropathy 61 Thal Dex 61 nonsignificant 61 P = .# 61 arterial thromboembolic events 61 HBeAg seroconversion 61 recurrent glioblastoma multiforme 61 HbA 1c levels 61 squamous histology 61 paroxysmal AF 61 sustained virologic response 61 follicular lymphomas 61 nonrandomized 61 PSA nadir 60 serum creatinine levels 60 adalimumab 60 TNF antagonist 60 interferon therapy 60 HBeAg positive 60 nonfatal MI 60 APTIVUS r 60 idraparinux 60 univariate analysis 60 drotrecogin alfa activated 60 desvenlafaxine succinate 60 sUA 60 genotypic resistance 60 radical nephrectomy 60 pCR 60 serum urate 60 PASI scores 60 HbA 1c 60 systolic dysfunction 60 undetectable HCV RNA 60 CANCIDAS 60 evaluable subjects 60 temsirolimus 60 undetectable HBV DNA 60 etanercept 60 mcg albinterferon alfa 2b 60 angiotensin converting enzyme inhibitors 60 platelet reactivity 60 Subgroup analyzes 60 statistically nonsignificant 60 hypercalcemia 60 complete cytogenetic response 60 MADRS score 60 timepoints 60 nilotinib 60 HER2 negative 60 neoadjuvant 60 fluvastatin 60 lymphocytosis 60 EGFR mutations 60 colorectal adenoma 60 lamivudine monotherapy 60 androgen deprivation 60 posttreatment 60 sustained virological response 60 adenoma recurrence 60 fibrinolysis 60 prespecified 60 composite endpoint 60 hepatic metastases 60 irbesartan 60 ertapenem 60 complete remissions 60 NIHSS 60 FDA defined valvulopathy 60 fulvestrant 60 intact parathyroid hormone 60 mcg BID 60 tumor shrinkage 60 antiangiogenic therapy 59 KRAS mutations 59 tipranavir ritonavir 59 recurrent GBM 59 nicardipine 59 IFN α 59 invasive aspergillosis 59 adefovir 59 hepatitis C genotype 59 F FDG PET 59 radiographic progression 59 plasma uric acid 59 prostate cancer CaP 59 advanced adenomas 59 NSTE ACS 59 poor metabolizers 59 bezafibrate 59 sotalol 59 graft occlusion 59 OPCAB 59 advanced adenoma 59 placebo 59 aspirin clopidogrel 59 subgroup analyzes 59 olmesartan 59 multivariate Cox 59 infarct size 59 HCV genotype 1 59 nab paclitaxel 59 peginterferon alfa 2b 59 EGFR TKI 59 HCV RESPOND 2 59 sirolimus eluting stents 59 amoxicillin clavulanate 59 p = #.# [003] 59 lamivudine refractory patients 59 progesterone receptor negative 59 dapagliflozin plus 59 TACE 59 T2DM 59 LEXIVA r 59 EBMT criteria 59 multivariate analyzes 59 thromboembolic events 59 voriconazole 59 resectable 59 K ras mutations 59 mg/m2 dose 59 clopidogrel 59 ximelagatran 59 CIMZIA ™ 59 tumor recurrence 59 caspofungin 59 pentoxifylline 59 lipid lowering therapy 59 adverse cytogenetics 59 imatinib 59 peginterferon alfa 2a 59 Subgroup analysis 59 aspartate aminotransferase AST 59 nonoperative 59 tapentadol ER 59 HCV SPRINT 59 salmeterol fluticasone 59 left ventricular dysfunction 59 DAPT 59 pT3 59 NYHA functional class 59 tolterodine ER 59 DAS# remission 59 rizatriptan 59 recurrent VTE 59 histologically confirmed 59 ischemic cardiomyopathy 59 mL/min/#.# m 2 59 relapsed MM 59 statistically significant p = 59 intravesical 59 virologic breakthrough 59 GOUT 59 VELCADE melphalan 59 certolizumab 59 posaconazole 59 perioperative complications 59 MACCE 59 nonischemic 58 fibrinolytic therapy 58 dacarbazine 58 nelfinavir 58 lung metastases 58 citalopram 58 adriamycin 58 secondary efficacy endpoint 58 elevated ALT 58 ACR# responses 58 tenecteplase 58 elevated LDH 58 nonoperative treatment 58 severe neutropenia 58 serum HBV DNA 58 surgical revascularization 58 heavily pretreated patients 58 pg ml 58 KRAS mutations occur 58 virologic responses 58 #mg BID [002] 58 primary percutaneous coronary 58 HBeAg negative 58 PCa 58 prospectively stratified 58 hyperalgesia 58 hypoperfusion 58 DMARDs 58 seropositive patients 58 postprocedure 58 % CI #.#-#.# [003] 58 glomerular filtration 58 RRMS patients 58 clodronate 58 REYATAZ r arm 58 nephrectomy 58 metformin monotherapy 58 cytotoxic therapy 58 chemoradiation 58 cilostazol 58 IFN beta 58 remission CR 58 efficacy endpoint 58 HER2 expression 58 imatinib therapy 58 postintervention 58 concurrent chemoradiation 58 achieved ACR# 58 latanoprost 58 PegIFN RBV 58 aminotransferase levels 58 paclitaxel eluting stents 58 achieved PASI 58 ACTEMRA TM 58 urine cytology 58 symptomatic VTE 58 nodular partial response 58 liver histology 58 rebleeding 58 glycated hemoglobin levels 58 timepoint 58 azacitidine 58 ACR# response 58 thrombotic events 58 apremilast 58 intravenous dosing 58 reach statistical significance 58 LV dysfunction 58 ejection fractions 58 clomipramine 58 patients evaluable 58 pegylated interferon 58 NMIBC 58 subclinical hypothyroidism 58 pegylated alpha interferon 58 CRp 58 Secondary endpoints 58 infarcts 58 renal tumors 58 relapsed SCLC 58 stage IIIb IV 58 ATACAND 58 hsCRP levels 58 antiarrhythmic drugs 58 plasma HCV RNA 58 hematologic toxicity 58 specific antigen PSA 58 typical antipsychotics 58 spirometric 58 refractory NSCLC 58 Index CDAI 58 gemcitabine Gemzar 58 -#.# log# 58 alteplase 58 ovarian carcinoma 58 TDF FTC 58 locoregional disease 58 5FU 58 baseline HbA1c 58 ARB telmisartan 58 HBV DNA 58 solifenacin 58 NNRTI resistance 58 secondary endpoint 58 tolvaptan 58 recurrent venous thromboembolism 58 superficial bladder cancer 58 myocardial ischemia 58 bortezomib refractory 58 nonmetastatic 58 mCRC patients 58 #mg QD [002] 58 neurologic progression 58 rosuvastatin #mg 58 fluorouracil 58 HCV genotype 58 postoperative chemotherapy 58 refractory AML 58 partial remissions 58 nortriptyline 58 ventricular dyssynchrony 58 Y BOCS 58 dalteparin 58 DLTs 58 HbA1c levels 58 multivariate adjustment 58 diuretic chlorthalidone 58 anemia hemoglobin 58 noninferior 58 reperfusion therapy 58 SUVmax 58 QRS duration 58 dacarbazine DTIC 58 thromboembolic 58 macroalbuminuria 58 lipid lowering therapies 58 intima media thickness 58 NYHA class 58 statistical significance p 58 SCIg 58 androgen suppression 57 neostigmine 57 mg ustekinumab 57 #mg BID [001] 57 GnRH agonists 57 chemoradiotherapy 57 carotid stenosis 57 PegIntron 57 adjunctive placebo 57 urinary N telopeptide 57 diastolic heart 57 Response Evaluation Criteria 57 lispro 57 MMSE score 57 nephrotoxicity 57 prodromal symptoms 57 daunorubicin 57 thyroglobulin 57 lumbar spine BMD 57 mg BID 57 ticagrelor 57 antihypertensive therapy 57 SVR# 57 gefitinib Iressa 57 Fludara 57 lopinavir r 57 recurrent ischemia 57 bortezomib 57 rituximab monotherapy 57 pegylated interferon alpha 57 abacavir lamivudine 57 sinus rhythm 57 cystectomy 57 nonadherence 57 eGFR 57 Virologic 57 estramustine 57 ASCT 57 systemic corticosteroids 57 DAS# scores 57 ibandronate 57 baseline FEV 57 infusional 57 coadministration 57 flutamide 57 coronary revascularization 57 corticosteroid therapy 57 neutrophil count 57 tHcy 57 homozygotes 57 placebo p 57 CIMZIA TM 57 eptifibatide 57 SCr 57 TT genotype 57 trastuzumab Herceptin ® 57 FDG PET 57 atheroma volume 57 fluticasone salmeterol 57 ACR Pedi 57 neovascular 57 disease modifying antirheumatic 57 locoregional recurrence 57 concomitant antibiotics 57 azathioprine 57 underwent resection 57 achieved CCyR 57 achieved sustained virologic 57 apolipoprotein B 57 peginterferon alfa 57 fibrinolytic 57 lymphadenectomy 57 interferon ribavirin 57 HCV RNA 57 serum PSA 57 preoperatively 57 BENICAR HCT 57 RGT arm 57 plasma pharmacokinetics 57 active comparator 57 ß blockers 57 saline placebo 57 thalidomide dexamethasone 57 renal toxicity 57 ALT flares 57 COPD exacerbations 57 unfractionated heparin 57 migalastat HCl 57 pulmonary exacerbation 57 4mg/kg 57 T#I [002] 57 mutated KRAS 57 reinfarction 57 target vessel revascularization 57 salmeterol HFA MDI 57 comparator arm 57 elevated troponin 57 % CI #.#-#.# [007] 57 lacosamide 57 ADAS Cog 57 hepatotoxicity 57 concomitant medications 57 NATRECOR ® 57 extensive metabolizers 57 Hepatitis C Antiviral 57 neutrophil counts 57 HBeAg 57 lamotrigine 57 recanalization 57 serum concentrations 57 randomized #:#:# 57 rhTSH 57 EGFR inhibitors 57 XELOX 57 ABC/3TC 57 OGTT 57 TOP2A 57 breast carcinoma 57 EDSS score 57 Traficet EN 57 methacholine challenge 57 CLL SLL 57 mITT population 57 FOLFOX 57 titrated glipizide 57 Ishak fibrosis score 57 riociguat 57 mg QD 57 fallopian tube cancers 57 allogeneic SCT 57 antiplatelet drugs 57 insulin detemir 57 treatment emergent AEs 57 cytogenetic responses 57 cytoreductive nephrectomy 57 rheumatoid factor 57 cranial irradiation 57 docetaxel chemotherapy 57 interferon alfa 57 octreotide LAR 57 IIIa inhibitor 57 NYHA Class II 57 rt PA 57 distant metastases 57 virologically 57 iodixanol 57 median PFS 57 tocilizumab 57 pamidronate 57 transaminases 57 sirolimus stent 57 SNP rs# [002] 57 myocardial infarctions 57 postdose 57 confidence interval #.#-#.# 57 FluCAM 57 NRTI 57 GP IIb IIIa inhibitors 57 carvedilol 57 oblimersen 57 IV NSCLC 57 metastatic malignant melanoma 57 annualized relapse 57 docetaxel prednisone 57 HGPIN 57 alanine aminotransferase ALT 57 coinfected patients 57 leukemia AML 57 haematologic 57 inflammatory lesions 57 Solid Tumors criteria 57 Elitek 57 abdominal pain abdominal discomfort 57 systemic embolism 57 aminotransferases 57 hypokalemia 57 NPH insulin 57 idarubicin 57 antibody titer 57 log# reduction 57 radiochemotherapy 57 receiving highly emetogenic 57 decitabine 57 echocardiographic parameters 57 nutlin 3a 56 CorVue ™ 56 serum ALT 56 mTOR inhibitors 56 glucose intolerant 56 HNSCC 56 revascularization procedures 56 8mg/kg 56 intravenous bisphosphonates 56 thromboembolic complications 56 d4T 56 coinfected 56 pegylated interferon alfa 56 lipid lowering medications 56 hippocampal atrophy 56 Hb A1C 56 hepatectomy 56 6 mercaptopurine 56 corticosteroids immunoglobulins 56 imatinib Gleevec 56 dobutamine 56 unresectable 56 events TEAEs 56 lopinavir r arm 56 QTc 56 histologies 56 ALT elevation 56 TNF inhibitors 56 LMWH 56 diameter stenosis 56 serum clusterin levels 56 non squamous 56 elotuzumab 56 Thrombolysis 56 fondaparinux 56 RECIST criteria 56 antihypertensive agents 56 placebo dexamethasone 56 TAXUS Express Stent 56 hypotensive 56 cediranib 56 mcg kg 56 allopurinol 56 proteinuria 56 PEG IFN 56 corticosteroid dose 56 micafungin 56 iloprost 56 vertebral fracture 56 goserelin 56 pegylated interferon ribavirin 56 Secondary efficacy endpoints 56 lymph node metastases 56 laboratory abnormalities 56 interferon alfa 2b 56 TLUS 56 MabCampath 56 anti TNF 56 renal dysfunction 56 EVIZON 56 albuminuria 56 antiplatelet therapy 56 oxycodone CR 56 febuxostat 56 NAbs 56 refractory ischemia 56 CHOP chemotherapy 56 mcg mL 56 inotropic 56 cTnT 56 cEVR 56 gout flares 56 cardiogenic shock 56 advanced neoplasia 56 serum phosphate levels 56 dosage regimens 56 ACR# ACR# 56 nmol L 56 ischemic lesions 56 Primary endpoints 56 hepatocellular carcinomas 56 remission induction 56 pramipexole 56 recurrent NSCLC 56 alkylating agents 56 hypogonadal men 56 diabetic gastroparesis 56 pT2 56 rHuEPO 56 docetaxel pretreated 56 mcg QD 56 thromboembolism 56 EBRT 56 stent implantation 56 elective PCI 56 ipsilateral stroke 56 plus COPEGUS 56 montelukast 56 mg dose 56 IOP lowering 56 epithelial ovarian cancer 56 divalproex sodium 56 moderate renal impairment 56 everolimus eluting stents 56 esomeprazole 56 chlorthalidone 56 RECIST Response Evaluation Criteria 56 lipid parameters 56 cTnI 56 #.#/#.# mmHg [001] 56 dose cytarabine 56 intensive statin therapy 56 vandetanib 56 mg RDEA# 56 doxorubicin docetaxel 56 confidence interval CI 56 VFEND 56 mitoxantrone 56 prespecified secondary 56 antiplatelet agents 56 ruboxistaurin 56 postoperative AF 56 EGFR TKIs 56 acute coronary syndromes ACS 56 squamous cell histology 56 ZOLINZA 56 castration resistant prostate cancer 56 p = #.# [002] 56 neoadjuvant therapy 56 prostate carcinoma 56 retreatment 56 Crohn Disease Activity 56 APOPTONE 56 response CCyR 56 melphalan prednisone 56 sunitinib 56 mitoxantrone chemotherapy 56 OAB symptoms 56 H. pylori eradication 56 thrombotic complications 56 cabazitaxel 56 Kinoid 56 sunitinib Sutent 56 dexrazoxane 56 imipramine 56 STRIDE PD 56 ritonavir boosted 56 prognostic factors 56 non squamous NSCLC 56 Cmax 56 ADAS cog 56 NATRECOR R 56 medically inoperable 56 interpersonal psychotherapy 56 IV bisphosphonates 56 oxycodone IR 56 resynchronization therapy 56 revascularizations 56 ABCB1 56 primary aldosteronism 56 postoperative complication 56 HAM D# scores 56 distant metastasis 56 anticholinergics 56 Telintra 56 MIRAPEX 56 AZT zidovudine Retrovir 56 dose dependently 56 metabolic parameters 56 grade cervical intraepithelial 56 cerebrovascular events 56 CrCl 56 histologically proven 56 HBV DNA levels 56 tacrolimus ointment 56 HSCT 56 ACEIs 56 iniparib 56 endoscopic remission 56 microbiological eradication 56 brain metastases 56 Baseline characteristics 56 DOXIL 55 zolmitriptan 55 liver transaminases 55 pancreatic adenocarcinoma 55 CK MB 55 venlafaxine XR 55 Solid Tumors RECIST 55 MMSE scores 55 HbA 1C 55 vinorelbine 55 trials RCTs 55 anticholinergic drugs 55 ventricular dysfunction 55 dosing cohort 55 cytoreduction 55 serum phosphorous 55 pg mL 55 leukopenia 55 VcMP 55 antithrombotic therapy 55 tolterodine 55 amisulpride 55 standard chemotherapy regimen 55 conventional antipsychotics 55 A1c levels 55 sorafenib Nexavar 55 stent thromboses 55 immunomodulatory therapy 55 IV tPA 55 trastuzumab 55 adjuvant radiotherapy 55 HER2 positive metastatic breast 55 randomized #:# 55 epithelial tumors 55 pneumonectomy 55 platelet inhibition 55 vasogenic edema 55 trans retinoic acid 55 carotid IMT 55 colorectal cancer liver metastases 55 arterial thrombosis 55 APTIVUS ritonavir 55 GAMMAGARD 55 AST ALT 55 Median PFS 55 virologic 55 adrenalectomy 55 atorvastatin #mg 55 LV ejection fraction 55 alanine aminotransferase 55 DFMO 55 serum phosphorus 55 leukocyte count 55 LDB CPR 55 aMCI 55 lipid lowering agents 55 QTc prolongation 55 reflux symptoms 55 placebo fluoxetine 55 Kaplan Meier curves 55 alkylating agent 55 conventional angiography 55 nonvertebral fractures 55 unresectable stage 55 limiting toxicity 55 euthyroid 55 adjuvant tamoxifen 55 docetaxel Taxotere ® 55 noncarriers 55 follicular NHL 55 tumor regressions 55 EGFR mutation positive 55 contralateral breast 55 ACR# [002] 55 stable angina 55 Pegylated Liposomal Doxorubicin 55 febrile neutropenia 55 lipid lowering drugs 55 TNF antagonists 55 hemodynamically significant 55 CTEPH 55 stratifying patients 55 COPAXONE R 55 pericardial effusion 55 taxane therapy 55 polyp recurrence 55 stable angina pectoris 55 OADs 55 preoperative PSA 55 oral corticosteroids 55 prednisone prednisolone plus 55 neoadjuvant treatment 55 metastatic malignant 55 pegylated interferon alfa 2b 55 LPV r 55 carboplatin paclitaxel 55 fosamprenavir 55 nondepressed 55 estrogen receptor negative 55 vasospasm 55 choroidal neovascularization 55 IL#B 55 multivariable analysis 55 sipuleucel T 55 glucose lowering 55 segment binary restenosis 55 clinically meaningful improvement 55 Non inferiority 55 mg TID 55 transaminase elevations 55 pomalidomide 55 plus methotrexate 55 FOLFIRI alone 55 hsCRP 55 relapsed AML 55 transaminase levels 55 HER2 amplification 55 CK # plasma concentrations 55 heterozygotes 55 pegylated interferons 55 hemoglobin A1c levels 55 mCRPC 55 p = NS 55 adefovir treated 55 levosimendan 55 Hematologic 55 hypomagnesemia 55 Ceplene/IL-2 55 HOMA IR 55 HDRS 55 peg interferon 55 PREZISTA r 55 UA NSTEMI 55 CC genotype 55 stenoses 55 HIV HCV coinfected 55 Stage IIIb 55 hepatorenal syndrome 55 hypogonadal 55 intracranial hemorrhage ICH 55 hydroxymethyl coenzyme 55 renal artery stenosis 55 chemoradiation therapy 55 TIMP 1 55 Fludarabine 55 log# copies mL 55 coronary stenoses 55 Dasatinib 55 metastatic HRPC 55 pelvic lymphadenectomy 55 FOLFOX6 55 isoproterenol 55 conventional coronary angiography 55 immunohistochemical analysis 55 unfractionated heparin UFH 55 mL/min/#.# m2 55 imatinib resistant 55 plus MTX 55 NRTI sparing 55 dasatinib Sprycel ® 55 statistically significant p 55 neointimal hyperplasia 55 mucosal healing 55 adjuvant chemotherapy 55 carcinoids 55 adjunctive ABILIFY 55 cerebral infarction 55 Serum creatinine 55 CIMZIA TM certolizumab pegol 55 dyspareunia 55 anagrelide 55 allogeneic stem cell 55 attain statistical significance 55 cardiac toxicity 55 KRAS mutant tumors 55 HIV RNA 55 lung metastasis 55 docetaxel 55 metastatic lung cancer 55 detrusor overactivity 55 thrombus aspiration 55 events AEs 55 uM 55 antiretroviral naive 55 Pegasys plus Copegus 55 sulfasalazine 55 CVD mortality 55 neointimal 55 rtPA 55 upper gastrointestinal bleeding 55 plus prednisone 55 candesartan 55 eosinophil count 55 lymph node involvement 55 TAXUS Stent 55 seronegative 55 MIs 55 liver biopsies 55 Virologic failure 55 thienopyridines 55 serum cortisol 55 dose cohorts 55 resected pancreatic cancer 55 BPH LUTS 55 MCyR 55 glomerular filtration rate 55 Neovascular AMD 55 valvulopathy 55 pyridostigmine 55 sulphonylureas 55 pharmacokinetic parameters 55 thienopyridine 55 NNRTIs 55 renal impairment 55 ICD implantation 55 T2 lesions 55 nmol liter 55 interferon IFN 55 prognostic variables 55 atazanavir ritonavir 55 microalbuminuria 55 fludarabine 55 tipranavir r 55 liver transplant recipients 55 achieve statistical significance 55 VAPRISOL 55 creatinine clearance 55 beclomethasone dipropionate 55 lactate dehydrogenase LDH 55 pulmonary toxicity 55 myocardial viability 55 ventricular tachyarrhythmia 55 SGRQ 55 differentiated thyroid 55 liver metastasis 55 Sustained Virologic Response 55 vessel occlusion 55 DAS# [002] 55 free survival PFS 55 aldosterone antagonist 55 lenalidomide dexamethasone 55 dopaminergic therapy